Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote "AGAINST" All of Sarissa's Proposals

GlobeNewswire February 13, 2023

Amarin Shareholders Invited to Webcast with Board and Management Team

GlobeNewswire February 13, 2023

Sarissa Capital Warns of Amarin's Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards

Business Wire February 13, 2023

Sarissa Capital Does Not Believe Amarin Cares About Shareholders

Business Wire February 9, 2023

Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card "AGAINST" Sarissa's Harmful Proposals

GlobeNewswire February 9, 2023

Sarissa Capital Highlights Amarin's Inaccurate and Misleading Statements

Business Wire February 7, 2023

Amarin Mails Letter to Shareholders Highlighting Sarissa's Myths vs. The Facts

GlobeNewswire February 6, 2023

Sarissa Capital Highlights Amarin's Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin

Business Wire February 3, 2023

Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership

GlobeNewswire February 2, 2023

Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders

Business Wire February 1, 2023

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

GlobeNewswire January 31, 2023

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

GlobeNewswire January 27, 2023

Amarin to Present at SVB Securities Global Biopharma Conference

GlobeNewswire January 27, 2023

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

GlobeNewswire January 19, 2023

Sarissa Capital Calls Out Amarin's Sham Board Refreshment

Business Wire January 18, 2023

Amarin Comments on Sarissa's Notice to Call a Special Meeting of Amarin Shareholders

GlobeNewswire January 11, 2023

Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen

Business Wire January 10, 2023

Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023

GlobeNewswire January 10, 2023

Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP

GlobeNewswire January 10, 2023

Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 14, 2022